Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2006

Open Access 01-12-2006 | Case report

Major combined electrolyte deficiency during therapy with low-dose Cisplatin, 5-Fluorouracil and Interferon alpha: report on several cases and review of the literature [ISRCTN62866759]

Authors: Katrin Hoffmann, Angela Marten, Katja Lindel, Stefan Fritz, Dirk Jager, Markus W Buchler, Jan Schmidt

Published in: BMC Cancer | Issue 1/2006

Login to get access

Abstract

Background

Low-dose Cisplatin and Interferon alpha treatment of solid tumors rarely has been associated with severe hypocalcaemia. To the authors knowledge the phenomenon has not been reported previously in patients with pancreatic carcinoma.

Case presentation

A patient with resected adenocarcinoma of the pancreas was treated with adjuvant radio-chemo-immunotherapy using a combination of low-dose Cisplatin, 5-Fluorouracil and Interferon alpha together with external beam radiation. Severe hypocalcaemia without signs of acute renal failure or electrolyte disturbance occurred within 2 days at the 4th week of treatment and required intensive care treatment.

Conclusion

Combination of biological and cytotoxic therapies may increase the incidence of severe hypocalcaemia in pancreatic cancer. Oncologists should remain attentive of this problem as more highly active regimes become available.
Appendix
Available only for authorised users
Literature
1.
Arany I, Safirstein RL: Cisplatin Nephrotoxocity. Seminars in Nephrology. 2003, 23: 460-464. 10.1016/S0270-9295(03)00089-5.CrossRefPubMed
2.
Fillastre JP, Raguenez-Viotte G: Cisplatin nephrotoxicity. Toxicol Lett. 1989, 46: 163-175. 10.1016/0378-4274(89)90125-2.CrossRefPubMed
3.
Cornelson TL, Reed E: Nephrotoxicity and hydration management for Cisplatin, Carboplatin und Ormaplatin. Gynecologic Oncology. 1993, 50: 147-158. 10.1006/gyno.1993.1184.CrossRef
4.
Goren MP: Cisplatin Nephrotoxicity affects Magnesium and Calcium Metabolism. Medical and Pediatric Oncology. 2003, 41: 186-189. 10.1002/mpo.10335.CrossRefPubMed
5.
Weiss-Guillet EM, Takala J, Jakob SM: Diagnosis and management of electrolyte emergencies. Best Practise, Research Clinical Endocrinology and Metabolism. 2003, 17: 623-651. 10.1016/S1521-690X(03)00056-3.CrossRef
6.
Pattou F, Combemale F, Fabre S, Carnaille B, Decloux M, Wemenau JL, Racadot A, Proye C: Hypocalcaemia following thyroid surgery: incidence and prediction of the outcome. World Journal of Surgery. 1998, 22: 718-724. 10.1007/s002689900459.CrossRefPubMed
7.
Prough DS: Physiologic acid-base and electrolyte changes in acute and chronic renal failure patients. Anesthesiol Clin North America. 2000, 18: 809-833. 10.1016/S0889-8537(05)70196-6.CrossRefPubMed
8.
Hadjis T, Grieff M, Lockhat D, Kaye M: Calcium metabolism in acute renal failure due to rhabdomyolysis. Clin Nephrol. 1993, 39: 22-27.PubMed
9.
Pitchumoni CS, Agarwal N, Jain NK: Systemic complications of acute pancreatitis. Am J Gastroenterol. 1988, 83: 597-606.PubMed
10.
Bazarbashi S, Rahal M, Raja MA, Weshi AE, Pai C, Ezzat A, Hanash K: A Pilot Trial of Combination Cisplatin, 5-Fluorouracil and Interferon-alpha in the Treatment of Advanced Oesophageal Carcinoma. Chemotherapy. 2002, 48: 211-216. 10.1159/000063870.CrossRefPubMed
11.
Picozzi VJ, Traverso LW: The Virginia Mason approach to localized pancreatic cancer. Surg Oncol Clin N Am. 2004, 663-674. 10.1016/j.soc.2004.06.002.
12.
Bazarbashi S, Pai C, Raja MA, Rahal M, Ezzat A, Hanash K: Phase II Trial of cisplatin, 5-fluorouracil, and interferon-alpha.2B as first line treatment of advanced urothelial cancer. Urologic Oncology. 2003, 21: 185-189.CrossRefPubMed
13.
Vokes EE, Ratain MJ, Mick R, McEvilly JM, Haraf D, Kozloff M, Hamasaki V, Weichselbaum RR, Panje RR, Wenig B: Cisplatin, Fluorouracil, and Leucovorin augmented by Interferon Alfa-2b in Head and Neck Cancer: A Clinical and Pharmacologic Analysis. Journal of Clinical Oncology. 1993, 11: 360-368.PubMed
14.
Knaebel HP, Maerten A, Schmidt J, Hoffmann K, Seiler C, Lindel K, Schmitz-Winnenthal HF, Fritz S, Hermann T, Goldschmidt H, Mansmann U, Debus J, Diehl V, Buchler MW: Phase III trial of postoperative cisplatin, interferon alpha-2b, and 5-FU combined with external radiation treatment versus 5-FU alone for patients with resected pancreatic carcinoma – CapRI: study protocoll (ISRCTN62866759). BMC Cancer. 2005, 5-
15.
Picozzi VJ, Kozarek RA, Traverso LW: Interferon-based adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma. American Journal of Surgery. 2003, 185: 476-480. 10.1016/S0002-9610(03)00051-5.CrossRefPubMed
16.
Dai LJ, Ritchie G, Kerstan D, Kang HS, Cole DE, Quamme GA: Magnesium transport in the renal distal convoluted tubule. Physiol Rev. 2001, 81: 51-84.PubMed
17.
Yasumasu T, Ueda T, Uozumi J, Mihara Y, Kumazawa J: Comparative study of cisplatin and carboplatin on pharmacokinetics, nephrotoxicity and effect on renal nuclear DNA synthesis in rats. Pharmacol Toxicol. 1992, 70: 143-147.CrossRefPubMed
18.
Hayes FA, Green AA, Senzer N, Pratt CB: Tetany: A Complication of Cis-Dichlorodiammineplatinum(II) Therapy. Cancer Treatment Reports. 1979, 63: 547-548.PubMed
19.
Jones GJ, Itri LM: Safety and Tolerance of Recombinant Interferon Alfa-2b (Roferon-A) in Cancer Patients. Cancer. 1986, 57: 1709-1715.CrossRefPubMed
20.
Wanebo HJ, Glicksman AS, Vezeridis MP, Clark J, Tibbetts L, Koness RJ, Levy A: Preoperative chemotherapy, radiotherapy, and surgical resection of locally advanced pancreatic cancer. Arch Surg. 2000, 135: 81-87. 10.1001/archsurg.135.1.81.CrossRefPubMed
21.
Moutardier V, Turrini O, Huiart L, Viret F, Giovannini MH, Magnin V, Lelong B, Bories E, Guiramand J, Sannini A, Giovannini M, Houvenaeghel C, Blache JL, Moutradier JC, Delpero JR: A reappraisal of preoperative chemoradiation for localized pancreatic head ductal adenocarcinoma in a 5-year single-institution experience. J Gastrointest Surg. 2004, 8: 502-510. 10.1016/j.gassur.2003.11.013.CrossRefPubMed
Metadata
Title
Major combined electrolyte deficiency during therapy with low-dose Cisplatin, 5-Fluorouracil and Interferon alpha: report on several cases and review of the literature [ISRCTN62866759]
Authors
Katrin Hoffmann
Angela Marten
Katja Lindel
Stefan Fritz
Dirk Jager
Markus W Buchler
Jan Schmidt
Publication date
01-12-2006
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2006
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-6-128

Other articles of this Issue 1/2006

BMC Cancer 1/2006 Go to the issue

Research article

Down regulation of PSA by C/EBPα is associated with loss of AR expression and inhibition of PSA promoter activity in the LNCaP cell Line

Research article

Evaluation of the kinase domain of c-KIT in canine cutaneous mast cell tumors

Research article

Single nucleotide polymorphisms of the APC gene and colorectal cancer risk: a case-control study in Taiwan

Research article

A novel role for 3, 4-dichloropropionanilide (DCPA) in the inhibition of prostate cancer cell migration, proliferation, and hypoxia-inducible factor 1alpha expression

Research article

Mutation analysis and characterization of ATR sequence variants in breast cancer cases from high-risk French Canadian breast/ovarian cancer families

Research article

A pilot, prospective evaluation of a novel alternative for maintenance therapy of breast cancer-associated lymphedema [ISRCTN76522412]
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits